News

Basket trials are designed to test therapies that target a specific genetic mutation found in the tumor, regardless of tumor histology. This emerging trend raises a number of key questions for the industry.

You can’t make every patient satisfied every time, but it’s worth a shot. Here are 10 simple strategies for providers to consider.

New research from Prophet shares five key shifts healthcare organizations can make in the move toward consumer-centricity.

A new survey has shocking results about consumer knowledge of health insurance.

Pharmaceutical industry observers are concerned about some of the drugs that were slashed from Express Scripts’ 2019 National Preferred Formulary.

COPD specialists have found that in-hospital and prompt post-discharge efforts can lessen costs-and the likelihood of hospital readmission. Here are three successful strategies.

COPD strikes 6.4% of Americans. While smoking is a big contributor, these seven other risk factors deserve more attention.

The first medication approved by FDA as part of an expedited generic drug program is one that has been in short supply.

Healthcare executives must understand mental health laws so they can do the right thing by their patients-and protect their bottom line.

Mental and substance abuse disorders account for a large chunk of America’s healthcare costs. Find out which of these diseases are the most costly.

If it's true that a picture is worth a thousand words, the same can be said for numbers.  For any healthcare executive, a look at relevant statistics can be revealing. Here are some of the top stats to know.

Although the act would not prohibit manufacturers from increasing prices, it could change the pricing landscape. Here’s why.

Artificial intelligence (AI) in healthcare is no longer a futuristic idea. Organizations are benefiting-on administrative and clinical levels-from practical adoptions that make cost savings and better patient care a reality.

When you are at the top or close to the peak in the leadership hierarchy, sometimes it’s hard to get proper advice. After all, with rank comes power, and many of your colleagues may be unwilling to speak the truth because they are protecting their own interests.

For many in healthcare, passion in the job comes from purpose, but sometimes, you may lose some of that fire. Here are some valuable tips from executive coaches that will help you rediscover that passion.

While we can’t help you cut down on your responsibilities, we can help you work more efficiently so that, hopefully, you won’t need to work so much.

Researchers and scientists continue to develop and test new treatments for these fatal conditions. Here’s a look at some major developments in these areas.

How healthcare executives can ensure they are always in the best position to take advantage of the next career opportunity.

From EHRs that didn’t fulfill promised savings to a system that still rewards volume over value, our experts examine what’s next in the quest to cut the fat from healthcare spending.

Managed Healthcare Executive asked key opinion leaders their thoughts on the drug rebate controversy. Here’s what they said.

FDA’s new guidance provides a roadmap for health executives on incorporating EHRs into clinical trials.

When it comes to promising areas in the treatment of lymphoma and other blood cancers, gene therapy may be at the top of the list. Here’s why.

Thinking out of the box leads to the best innovation sometimes. Here are lessons healthcare leaders say can be learned from other industries.

Artificial intelligence is about to do what we hoped to see technology do in the last decade for the health industry: Empower organizations and clinicians to improve the health, outcomes, and experience of care for more people in less time and at lower cost.

Two oncology practices have wish list items for payers. Find out what they are.

The 30-year old regulation is in desperate need of modernization to fall in line with the changing needs of healthcare.

A new survey from HealthMine reveals shocking findings about connecting with Medicare Advantage members who have chronic conditions.

FDA okayed iobenguane I 131 (Azedra, Progenics Pharmaceuticals) injection for IV use to treat rare tumors of the adrenal gland.